Recombinant von Willebrand Factor Shows Effectiveness in Treating Surgery-Related Bleeds in Adults with VWD

Strategic Insights -

Research on von Willebrand disease (VWD) has led to significant advancements in treatment and management of the condition. A recent study published in the European Journal of Haematology has explored the use of recombinant von Willebrand factor (rVWF) in adults with VWD undergoing surgery. The study aimed to investigate treatment outcomes, healthcare resource utilisation, and patient satisfaction in this patient population. The study's findings have shed light on the effectiveness and safety profile of rVWF in a surgical setting.

Key Takeaways:

  • The study included 20 patients (55.0% female, 90.0% White/Caucasian, mean age 56.7 years) with congenital VWD who received rVWF for the prevention/treatment of surgery-related bleeds.
  • All applicable bleeds were successfully treated with normal haemostasis achieved, and only four patients received exogenous factor VIII in addition to rVWF at index.
  • There were no treatment switches, no likely treatment-related complications, and physician-rated treatment satisfaction was 'excellent' (36.7%) or 'good' (63.3%) for all rVWF-treated surgery-related bleeds.
  • The study's results support the effectiveness and safety profile of rVWF in a surgical setting in adults with VWD.
  • The authors included Heena Howitt, Mike Laffan, Cheryl Jones, Sarah Brighton, Rosa Willock, Anna Sanigorska, and Oliver Heard, with Heena Howitt being the lead author.
  • The study's findings have significant implications for the treatment and management of VWD in adults undergoing surgery.

Statistics:

  • The study included 20 patients with congenital VWD.
  • 90.0% of the patients were from the White/Caucasian ethnicity.
  • Mean age of the patients was 56.7 years.
  • 55.0% of the patients were female.
  • All applicable bleeds were successfully treated.
  • 36.7% of the patients rated their treatment satisfaction as 'excellent', while 63.3% rated it as 'good'.
  • There were no treatment switches, no likely treatment-related complications.

Sources:

  • Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom. European Journal of Haematology, 2025.
  • European Journal of Haematology, Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.
  • NewsRx. Reports from Heena Howitt and Colleagues Advance Knowledge in Von Willebrand Disease (Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the ...). Hematology Week. October 20, 2025; p 1465.